NOVA SCOTIA PRENATAL RECORD 1

An updated copy of this record should remain with the woman throughout her pregnancy.

For copies contact: Reproductive Care Program, 5991 Spring Garden Rd., Suite 700, Halifax, NS B3H 1Y6 Tel: 470-6798 rcp.nshealth.ca or order by email: RCP@NSHealth.ca

DEMOGRAPHICS	
Patient's Name: Maiden Name:	
DOB: Age: HC#:	
Race/Ethnicity: \square Acadian \square African Canadian \square Asian \square Caucasian \square First Nations	☐ Hispanic
☐ Jewish ☐ Mediterranean ☐ Middle Eastern ☐ Québécois ☐ Other:	
Language: 🗆 Eng 🗆 French 🗆 Arabic 🗀 Other:	
Marital Status: Highest Level of Education Completed:	
Employed: ☐ Y ☐ N Type of work:	Partner's Name: Age:
Address:	Race/Ethnicity: □ Acadian □ African Canadian □ Asian □ Caucasian
	☐ First Nations ☐ Hispanic ☐ Jewish ☐ Mediterranean
Contact Telephone Numbers: (H)	(W) Middle Eastern Québécois Other:
Primary Care Provider(s): Physician/Midwife/Nurse:	Language: □ Eng □ French □ Arabic □ Other:
Baby's Physician:	Employed: □ Y □ N Type of work:
PREGNANCY DATING EDD (Best Estin	nate):
Positive Pregnancy Test:	Conception Date if known (ie. IVF):
LMP Date: Sure?: 🗆 Y 🗀 N Length of cycle: Re	gular:
EDD based on LMP:	(1st tri. U/S should be completed if uncertain LMP or irregular cycles)
Dating U/S: Gest at time of U/S:	EDD based on U/S:
OBSTETRICAL HISTORY Gravida Para	Abort SB NND
Date Place Gest Mode of Del	Complications/Comments Birth Wt Sex Present Health
PRESENT PREGNANCY Y N PROBLEMS/COMM	MENTS/DETAILS/REFERRALS PAST ILLNESS Y N
Current Medications	Operations
Pre-pregnancy Medications	Anaes Problems
Pre-conceptional Folic Acid	Blood/products
Depression/anxiety	Respiratory
Bleeding	Renal disease
Received Immune Globulin	Diabetes
Pyrexia	Cardiac
Infections (e.g. UTI, STI)	Gynecologic
Nausea/vomiting	Thromboembolism
Smoking pre-preg (#/day)	Hypertension
Smoking now (#/day)	CNS disorder/migraine
Wishing to quit	Psychiatric disorder/eating disorder
Alcohol use	Substance use
Substance use	STI
TPTL	Other
FFN Sent	
ALLERGIES Y N	

Body Mass Index Table – Use Pre-Pregnancy Weight													
UNDERWEIGHT NORMAL				OVERWEIGHT			OBESE		VERY OBESE				
WE	IGHT	HEIGHT IN FEET/INCHES AND METERS											
LB	KG	4'8" 1.42m	4'10" 1.47m	5'0" 1.52m	5'2" 1.57m	5'4" 1.63m	5'6" 1.68m	5'8" 1.73m	5'10" 1.78m	6'0" 1.83m	6'2" 1.88m	6'4" 1.93m	6'6" 1.98m
100	45.4	22.4	20.9	19.5	18.3	17.2	16.1	15.2	14.3	13.6	12.8	12.2	11.6
105	47.6	23.5	21.9	20.5	19.2	18.0	16.9	16.0	15.1	14.2	13.5	12.8	12.1
110	49.9	24.7	23.0	21.5	20.1	18.9	17.8	16.7	15.8	14.9	14.1	13.4	12.7
115	52.2	25.8	24.0	22.5	21.0	19.7	18.6	17.5	16.5	15.6	14.8	14.0	13.3
120	54.4	26.9	25.1	23.4	21.9	20.6	19.4	18.2	17.2	16.3	15.4	14.6	13.9
125	56.7	28.0	26.1	24.4	22.9	21.5	20.2	19.0	17.9	17.0	16.0	15.2	14.4
130	59.0	29.1	27.2	25.4	23.8	22.3	21.0	19.8	18.7	17.6	16.7	15.8	15.0
135	61.2	30.3	28.2	26.4	24.7	23.2	21.8	20.5	19.4	18.3	17.3	16.4	15.6
140	63.5	31.4	29.3	27.3	25.6	24.0	22.6	21.3	20.1	19.0	18.0	17.0	16.2
145	65.8	32.5	30.3	28.3	26.5	24.9	23.4	22.0	20.8	19.7	18.6	17.6	16.8
150	68.0	33.6	31.3	29.3	27.4	25.7	24.2	22.8	21.5	20.3	19.3	18.3	17.3
155	70.3	34.7	32.4	30.3	28.3	26.6	25.0	23.6	22.2	21.0	19.9	18.9	17.9
160	72.6	35.9	33.4	31.2	29.3	27.5	25.8	24.3	23.0	21.7	20.5	19.5	18.5
165	74.8	37.0	34.5	32.2	30.2	28.3	26.6	25.1	23.7	22.4	21.2	20.1	19.1
170	77.1	38.1	35.5	33.2	31.1	29.2	27.4	25.8	24.4	23.1	21.8	20.7	19.6
175	79.4	39.2	36.6	34.2	32.0	30.0	28.2	26.6	25.1	23.7	22.5	21.3	20.2
180	81.6	40.4	37.6	35.2	32.9	30.9	29.1	27.4	25.8	24.4	23.1	21.9	20.8
185	83.9	41.5	38.7	36.1	33.8	31.8	29.9	28.1	26.5	25.1	23.8	22.5	21.4
190	86.2	42.6	39.7	37.1	34.8	32.6	30.7	28.9	27.3	25.8	24.4	23.1	22.0
195	88.5	43.7	40.8	38.1	35.7	33.5	31.5	29.6	28.0	26.4	25.0	23.7	22.5
200	90.7	44.8	41.8	39.1	36.6	34.3	32.3	30.4	28.7	27.1	25.7	24.3	23.1
205	93.0	46.0	42.8	40.0	37.5	35.2	33.1	31.2	29.4	27.8	26.3	25.0	23.7
210	95.3	47.1	43.9	41.0	38.4	36.0	33.9	31.9	30.1	28.5	27.0	25.6	24.3
215	97.5	48.2	44.9	42.0	39.3	36.9	34.7	32.7	30.8	29.2	27.6	26.2	24.8
220	99.8	49.3	46.0	43.0	40.2	37.8	35.5	33.5	31.6	29.8	28.2	26.8	25.4
225	102.1	50.4	47.0	43.9	41.2	38.6	36.3	34.2	32.3	30.5	28.9	27.4	26.0
230	104.3	51.6	48.1	44.9	42.1	39.5	37.1	35.0	33.0	31.2	29.5	28.0	26.6
235	106.6	52.7	49.1	45.9	43.0	40.3	37.9	35.7	33.7	31.9	30.2	28.6	27.2
240	108.9	53.8	50.2	46.9	43.9	41.2	38.7	36.5	34.4	32.5	30.8	29.2	27.7
245	111.1	54.9	51.2	47.8	44.8	42.1	39.5	37.3	35.2	33.2	31.5	29.8	28.3

<20: Wt gain of 28-40 lbs (1 lb/wk in 2nd and 3rd trimesters)

20-27: Wt gain of 25-35 lbs (0.75 lb/wk in 2nd and 3rd trimesters)

27-29: Wt gain of 15-25 lbs (0.5 lb/wk in 2nd and 3rd trimesters)

>29: Wt gain of no more than 15 lbs

For those patients with a pre-pregnancy weight greater than 245 lbs or 111.1 kg, there is an alternate imperial-only BMI chart in the companion document (Appendix H) that includes pre-pregnancy weight up to 328 lbs. The BMI may also be calculated using pounds and inches, multiply your weight by 703, divide by your height in inches, and then divide by your height again (lbs X 703/inches/inches)

Using kilograms and metres, divide your weight in kilograms by the square of your height in metres (Kg/m2)



NOVA SCOTIA PRENATAL RECORD 2

PATIENT'S NAME	•			EDD:				
PHYSICAL ASS	ESSMENT							
Pre-preg Wt			Height	ВР	P			
BMI (early diabetic sc	reen for those with	ВМІ	> 30)					
Head and Neck			Heart					
Breast			Lungs					
Abdomen			Extrem	nities				
Pelvis			Corpus					
Cervix			Adnex					
PSYCHOSOCIAL/EN	NVIRONMENTAL	Υ	N		COMMENTS	/DETAILS	GENETIC SCREENING	Y
Activity limitations						-	Age ≥ 35 at delivery	
Nutrition concern/Foo	od security		\Box				Fam Hx congenital anomalies/birth defects	\top
Adequate support	,		\Box				Fam Hx inherited disease/disorder	+
Housing security			H				Fam Hx Diabetes	+
Abuse			\Box				Ethnic risk	+
Social assistance requ	ired		+				Genetic screening discussed	+
Referral(s)	ii vu		+	To:			Genetic screening declined	+
NOIOIIUI(3)			+	To:			Consanguinity discussed	+
EDUCATION/DI							Consumy discossed	
Prenatal Education: Flu Vaccine (offer duri Plan to Breast Feed: Previous Breast Feedir	□ Y □ N Type: ing flu season): □ □ Y □ N ng Experience: □ \	Y [□ N N	Pr He Int Pr	regnancy expectati ealthy Eating/Phy stercourse reterm Labour Sign	sical Activity s and Symptoms	Newborn Screening Parenting Daily Multivitamin Containing Folic Acid & In Cord Blood Banking	ron
Discussed Benefits of	-				abor/Birth Expecto	tions		_
ANTENATAL SCI	REENING: SEE	RE	VERS	SE FOR GUIDELINES				
FIRST	OFFERED TO ALL WON				<u>WEN</u>		OFFERED TO SOME WOMEN	
PRENATAL	Hgb				Rubella	(if immune status unknown)	Varicella	
VISIT	HepB Antiger	1			Chlamy	dia	Diabetic Screen	
	Syphilis/VDF	RL.			Gonorrh	ea	Father's Rh	
	ABO/Rh				Urine C	22		
	HIV □ dis	CUSS	ed \square	accepted 🗆 declined				
	PAP Date:			Results				
9-13+6	*MST □ discussed □ declined □ completed					RESULTS		
WEEKS	*EPR ☐ discussed ☐ declined ☐ completed							
15-20+6	*MST		discus	sed 🗆 declined 🗆 completed				
WEEKS	* See reverse	e for	definitio	ons				
18-21	USD			sed 🗆 declined 🗆 completed				
WEEKS				,				
24-28	OFFERED 1	Ο Δ	LL W	OMEN	OFFE	RED TO SOME WOMEN		
WEEKS	Hgb					□ done prev. □ declined		
	"	on (1	hour P	C 50g glucose screen)		_ dono prov documed		
					ould he drawn nri	or to administration of Rh immune globulin)		
28 WEEKS	Rho(D) Immi				Date:	n to autilitionation of kit littinotic groublill)		
		טווע (ווווטמטונו	OLACII TIE2 TIMO				
35-37 WEEKS	GBS Date:				Result		☐ declined	
SPECIAL PROCEDI	URES/TESTS							
GTT: ☐ Yes ☐ No	Date:				Results	:		
Amniocentesis/CVS Do	ate:				Result	:		

Guidelines for Antenatal Screening and Testing

First Prenatal Visit

- HgB, HepB antigen, Syphilis
- Group/type and antibody screen
- Rubella: Do if immune status is unknown. Vaccination is recommended post partum if non-immune.
- Varicella: Do if there is no history of infection, vaccination, or positive serology. Vaccination is recommended post partum if non-immune.
- Human Immunodeficiancy Virus: HIV counseling is required, testing is voluntary.
- Urine C&S (or a urinalysis followed by a C&S if the analysis is positive)
- Cervical Cytology: if not done in the last 12 months
- Cervical screening for gonorrhea and chlamydia (see companion document for information about screening)
- Diabetes glucose screen (also known as PC50 or Trutol): Appropriate for women at risk for GDM. Risk factors include glycosuria, obesity, multiple gestation, previous GDM, previous LGA baby, history of unexplained stillbirth, family history of diabetes in a first degree relative, ethnic predisposition, polyhydramnios
- If twins or multiples suspected, ultrasound for chorionicity (plus or minus nuchal translucency as MST not applicable for multiple gestations)
- If uncertain LMP or irregular cycles, a 1st trimester dating U/S should be completed.

9-13+6 Weeks:

MST: 1st trimester maternal serum testing should be offered to all women regardless of age. Note: 2nd trimester testing must be performed in conjunction with 1st trimester testing for an integrated screen.

11-13+6 Weeks

Early Pregnancy Review (EPR): Women with specific risk factors and all women over age 35 years at their EDD should be offered an early pregnancy review (EPR) in the Fetal Assessment and Treatment Centre (FATC) at the IWK Health Centre. An EPR is an ultrasound that reviews viability, dates, early development and assesses for fetal abnormalities through specific markers, particularly a nuchal translucency. This review is best if used in conjunction with the maternal serum test for assessment of risk for Trisomy 21.

15-20+6 Weeks:

MST: 2nd trimester testing should be offered to all women regardless of age.

Integrated Maternal Serum Test: This test incorporates maternal age, first trimester maternal serum test (MST) and second trimester maternal serum test (MST) into a combined or integrated assessment of risk for fetal chromosomal abnormalities, open fetal defects such as spina bifida and placental abnormalities.

Integrated Prenatal Test: This test is the same as above but also includes the EPR in the integration

18-21 Weeks:

Ultrasound: should include fetal biometry, amniotic fluid volume, placentation, anatomical review for anomalies, and markers for fetal aneuploidy. (offered to all women)

24-28 Weeks:

- Repeat HgB
- Diabetes (glucose) screen: For all women, including those at risk for GDM whose initial screen was negative
- Antibody screen: For women who are Rh + (see below for Rh women)
- HIV: Women at risk for HIV or those who declined first trimester screening should be offered this opportunity for screening

Please note at 28 Weeks:

For Rh — women: Repeat antibody screen, regardless of partner's Rh type. If partner is Rh + or has an unknown Rh status, the antibody screen should be done prior to the administration of Rho(D) Immune Globulin.

35-37 Weeks:

Group B Strep: Vaginal/rectal swab by patient or physician

After 41 weeks

- Biophysical profile or NST and amniotic fluid volume
- Induction of labour



NOVA SCOTIA PRENATAL RECORD 3

PATIENT'S NAM	NE: EDD:								
PROBLEM LIST/CARE PLAN									
Issue	Plan (Follow-up/Consults)								

Date Weight Urine P/S BP Gest Fundu Pres. FHR Ferdular Miss Mi															
Dote Weight Unine												L VISITS			
	Date	Weight	Urine P/S	BP	Gest (wks)	Fundal height	Pres.	FHR	Fetal	Cigs /day	Next visit	Comments			
			1/3		(1110)	noigin			movemen	/ uu y	VISII				